InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-24 | 2026-02-25 | FROST PHILLIP MD ET AL | Director | Purchase | 20.0K | $1.00 | $20K | 1.91M | View ↗ | |
| 2026-02-06 | 2026-02-09 | FROST PHILLIP MD ET AL | Director | Purchase | 50.0K | $0.95 | $47K | 1.89M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development | $5.05B-59.7% | $12.54B-17.4% | $15.17B+122309.6% | $12.4M |
| General and administrative | $3.96B-25.8% | $5.34B-10.8% | $5.99B+104164.6% | $5.7M |
| Total operating expenses | $9.02B-49.6% | $17.88B-3.7% | $18.56B+47696.7% | $38.8M |
| Loss from operations | -$9.02B+49.6% | -$17.88B+3.7% | -$18.56B-47696.7% | -$38.8M |
| Interest income, net | $134.0M-75.0% | $537.0M-16.1% | $640.0M | — |
| Foreign exchange gain (loss) | $54.0M+133.1% | -$163.0M | — | — |
| Total other income, net | $188.0M-49.7% | $374.0M-35.0% | $575.0M | — |
| Net loss | -$8.83B+49.5% | -$17.50B+2.7% | -$17.98B-46206.4% | -$38.8M |
| Net loss per common share, basic | -$780+54.7% | -$2K+8.0% | -$2K+60.8% | -$5K |
| Net loss per common share, diluted | -$780+54.7% | -$2K+8.0% | -$2K+60.8% | -$5K |
| Weighted average number of common shares outstanding, basic | $11.3M+11.0% | $10.2M | — | — |
| Weighted average number of common shares outstanding, diluted | $11.3M+11.0% | $10.2M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection
COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention
We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive